Market Capitalization (Millions $) |
17 |
Shares
Outstanding (Millions) |
99 |
Employees |
- |
Revenues (TTM) (Millions $) |
47 |
Net Income (TTM) (Millions $) |
-28 |
Cash Flow (TTM) (Millions $) |
-16 |
Capital Exp. (TTM) (Millions $) |
0 |
Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc. is a biotechnology company based in the United States. The company focuses on the discovery and development of Anticalin-based drugs, which are therapeutic proteins derived from lipocalins, a type of human protein. Pieris Pharmaceuticals' drugs are designed to target specific diseases and bind to disease-causing proteins, offering potential treatments for a range of conditions including cancer, respiratory diseases, and metabolic disorders. The company aims to leverage its proprietary Anticalin platform to develop innovative therapies that address unmet medical needs.
Company Address: 225 Franklin Street, 26th Floor Boston 2110 MA
Company Phone Number: 246-8998 Stock Exchange / Ticker: NASDAQ PIRS
PIRS is expected to report next financial results on March 30, 2024. |
|
|